Paid Clinical Trials Rhode Island
Discover 468 paid clinical trials in Rhode Island. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Single vs. MultipleComparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Sponsor:
Weill Medical College of Cornell University
Location:
Code:
NCT04124120
Conditions
Heart Diseases
Coronary Artery Disease
Coronary Artery Bypass Grafting
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Single arterial graft
Multiple arterial grafting
PegozaferminA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Sponsor:
89bio, Inc.
Location:
Code:
NCT06419374
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Pegozafermin
Placebo
Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
SeralutinibEfficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
Observational StudyTrauma-Informed Peer Aggression and Dating Violence Prevention for Preteens Receiving Intensive Mental Health Services
Sponsor:
Rhode Island Hospital
Location:
Code:
NCT06769282
Conditions
Aggression Childhood
Teen Dating Violence
Eligibility Criteria
Sex: All
Age: 11 - 13
Healthy Volunteers: Not accepted
Interventions
Experimental: Intervention (SPARE) plus Treatment as Usual
Treatment as Usual (TAU)
Substance Use PreventionSubstance Use Prevention for Youth With Parents in Recovery
Sponsor:
Brown University
Location:
Code:
NCT05397691
Conditions
Substance Use Disorders
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Modified Family Talk
Control-like parameter estimation
BLU-5937A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Sponsor:
Bellus Health Inc. - a GSK company
Location:
Code:
NCT05599191
Conditions
Refractory Chronic Cough
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BLU-5937
Placebo
SaruparibSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Sponsor:
AstraZeneca
Location:
Code:
NCT06120491
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Saruparib
Placebo
Abiraterone Acetate
Darolutamide
Enzalutamide
Abemaciclib, Temozolomide, Neratinib, CC115, QBS10072SINdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Sponsor:
Patrick Wen, MD
Location:
Code:
NCT02977780
Conditions
Glioblastoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Temozolomide
Neratinib
QBS10072S